Thank you, Dr. Ouellette. Sure, I can add to that.
Certainly, the surveillance we do across the country for AMR is good, but it could be a lot better. For example, most of the surveillance we have for human illness is based in hospital settings in terms of what kinds of infections are prevalent. To be honest, we don't have very good data on what happens in the community setting, as I said in my opening remarks. For example, for sexually transmitted infections like neisseria gonorrhoeae, there's certainly a lot of resistance out there, but we don't really have a good, complete picture.
I think your question about the antimicrobial use links in part to having a better understanding of which diseases and infections are prevalent in different parts of the country. We need to link that up with antimicrobial use and prescription practices to see if they actually match up in terms of appropriate prescription based on what actual diseases and infections are occurring. Those are areas that we certainly intend to move forward on with our partners to strengthen, both on the disease outcomes in terms of the community and hospital settings, but also in terms of antimicrobial use and prescription practices.